Questcor Pharmaceuticals — Corporate Update (June 2012)
17 slides from Questcor Pharmaceuticals's corporate update, Jun 19, 2012
Slide 1: Investor Update – Rheumatology
Exhibit 99.2 NASDAQ: QCOR June 14, 2012 Investor Update –Rheumatology 1 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performanc
Slide 3: Acthar Has Multiple Approved, On-Label Rheumatology-Related Indications
Acthar Has Multiple Approved , On-Label Rheumatology-Related Indications Rheumatology-Related Indications in Acthar PI As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rhe
Slide 4: Rheumatology: Estimated Patient Populations
Rheumatology: Estimated Patient Populations* Total Estimated Estimated Target Indication US Population Acthar Population Dermatomyositis/Polymyositis 66K ~26K Systemic Lupus Erythematosus 250K ~50K-100K Rheumatoid Arthritis 1.3M ~50K Psoriatic Arthritis 500K ~40K Juvenile Rheumatoid Arthritis 300K -
Slide 5: Dermatomyositis and Polymyositis Disease State Overview and Treatment Experience with Acthar
Dermatomyositis (DM) and Polymyositis (PM) Disease State Overview and Brief Summary of Treatment Experience with Acthar Todd Levine, M.D. Phoenix Neurological Associates Director of the ALS Clinic and Co-Director of Neurophysiology at Banner Good Samaritan Medical Center Assistant Professor of Neuro
Slide 6: Dermatomyositis and Polymyositis: Serious Autoimmune Disorders
Dermatomyositis and Polymyositis: Serious Autoimmune Disorders • Rare neuromuscular conditions; high unmet need • Both involve autoimmune inflammatory myopathies (inflammation of muscle) – DM also characterized by skin manifestations • Treated by both Rheumatologists and Neurologists • Begins as ins
Slide 7: DM/PM Patients Underserved By Current Therapies
DM/PM Patients Underserved By Current Therapies • Current treatments include steroids, immunosuppressants, IVIG, rituximab – Only Acthar and steroids are FDA-approved in the treatment of DM/PM • Many patients do not respond to, or are unable to tolerate, corticosteroids and immunosuppressant therapy
Slide 8: Acthar Treatment in DM and PM: Patient Types and Dosing
Acthar Treatment in DM and PM: Patient Types and Dosing • Report of 5 cases of refractory DM and PM treated with Acthar recently published in Drug Development, Design and Therapy • All patients had been unresponsive and/or unable to tolerate a variety of current therapies used to treat DM and PM – A
Slide 9: Acthar Treatment in DM and PM: Overall Observed Results (n=5)
Acthar Treatment in DM and PM: Overall Observed Results (n=5) • All patients experienced clinically significant improvement – Muscle strength improved in all 5 patients – Skin manifestations improved in all 3 DM patients • All patients reported improvements with daily living activities – 3 patientsw
Slide 10: DM Patient Example: History
DM Patient Example: History • Treatment history after Dx included prednisone, mycophenolate, azathioprine, IVIG, cyclosporine, and methotrexate • Began treating patient in 2004 – Positive response to rituximab, cyclosporine, and IVIG – Maintained on IVIG and cyclosporine until a relapse in 2006 • Pa
Slide 11: DM Patient Example: Initial Acthar Treatment
DM Patient Example: Initial Acthar Treatment • Patient received Acthar 80 U 2x/wk for 12 weeks (no titration) – Concomitant medication: IVIG 2 gm/kg/mo and azathioprine 200 mg/day – Patient tolerated Acthar treatment well with no significant side effects • Positive response to Acthar treatment – Mus
Slide 12: DM Patient Example: Follow-Up Acthar Treatment
DM Patient Example: Follow-Up Acthar Treatment • ~6 months after completing Acthar treatment the patient experienced increased weakness in proximal leg muscles (3+/5) • Patient then given tacrolimus for 6 months with no results • Patient then began a second course of treatment with Acthar – Dosed 80
Slide 13: DM/PM Commercial Opportunity
DM/PM Commercial Opportunity Steve Cartt Chief Operating Officer 13 13
Slide 14: DM/PM Represents Significant Commercial Opportunity Due to High Unmet Need
DM/PM Represents Significant Commercial Opportunity Due to High Unmet Need • ~66,000 DM/PM patients in the US, based upon key epidemiological study which found a prevalence rate of 21.5 cases per 100,000 population (Bernatsky 2009) – Estimate supported by Questcor survey of treating physicians (N=19
Slide 15: Questcor Rheumatology Plans
Questcor Rheumatology Plans • Pilot rheumatology selling effort beginning mid-July – National Sales Director and manager positions (2) have been filled, with hiring/training of 12 experienced Rheum reps in progress – Initial promotional effort focused on DM/PM • Potential to expand Rheumatology Sale
Slide 16: Rheumatology: Estimated Patient Populations
Rheumatology: Estimated Patient Populations* Total Estimated Estimated Target Indication US Population Acthar Population Dermatomyositis/Polymyositis 66K ~26K Systemic Lupus Erythematosus 250K ~50K-100K Rheumatoid Arthritis 1.3M ~50K Psoriatic Arthritis 500K ~40K Juvenile Rheumatoid Arthritis 300K -
Slide 17: NASDAQ: QCOR
NASDAQ: QCOR June 14, 2012 Investor Update –Rheumatology 17 17
Questcor Pharmaceuticals — Corporate Update (June 2012) on 6ix